Brisbane-based vaccine patch company Vaxxas is developing the first room temperature-stable needleless vaccine for one of the world’s most common cold-like diseases, weeks after launching efforts to raise $100 million. On Tuesday, Vaxxas announced it had received a global licence from the United States National Institutes of Health (NIH). The company will now prepare for the first clinical trial for a room temperature-stable needleless vaccine for Respiratory Syncytial Virus (RSV). Vaxxas chief executive David Hoey said the “Vaxxas needle-free technology to eliminate the need for refrigerated distribution and enable self-administration”.
Brandon How is a reporter for InnovationAus.com, focusing on national innovation and technology news in Australia. With a keen interest in the intersection of business, technology, and policy, Brandon covers a wide range of topics including startups, emerging technologies, government initiatives, and industry trends.